ATE262586T1 - Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin - Google Patents
Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzinInfo
- Publication number
- ATE262586T1 ATE262586T1 AT95943342T AT95943342T ATE262586T1 AT E262586 T1 ATE262586 T1 AT E262586T1 AT 95943342 T AT95943342 T AT 95943342T AT 95943342 T AT95943342 T AT 95943342T AT E262586 T1 ATE262586 T1 AT E262586T1
- Authority
- AT
- Austria
- Prior art keywords
- egf receptor
- type iii
- mutant egf
- fusion junction
- junction type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34752094A | 1994-11-28 | 1994-11-28 | |
| PCT/US1995/015401 WO1996016988A1 (en) | 1994-11-28 | 1995-11-28 | Reagents and processes for targeting mutant epidermal growth factor receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE262586T1 true ATE262586T1 (de) | 2004-04-15 |
Family
ID=23364052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95943342T ATE262586T1 (de) | 1994-11-28 | 1995-11-28 | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6224868B1 (de) |
| EP (1) | EP0796277B1 (de) |
| JP (2) | JP4620808B2 (de) |
| AT (1) | ATE262586T1 (de) |
| CA (1) | CA2206343C (de) |
| DE (1) | DE69532767T2 (de) |
| WO (1) | WO1996016988A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE262586T1 (de) * | 1994-11-28 | 2004-04-15 | Univ Jefferson | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin |
| US5914269A (en) | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
| CA2380631A1 (en) * | 1999-07-30 | 2001-02-08 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| EP1276771A4 (de) * | 2000-03-10 | 2003-06-04 | Thomas Jefferson Univarsity | Empfindlicher nachweis von egfr-mutanten und wildtyp durch spezifische elisa-nachweise in jeglicher biologischer probe |
| US6444465B1 (en) | 2000-09-29 | 2002-09-03 | Isis Pharmaceuticals, Inc. | Antinsense modulation of Her-1 expression |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DK1392359T4 (da) | 2001-05-11 | 2013-06-10 | Ludwig Inst For Cancer Res Ltd | Specifikke bindingsproteiner og deres anvendelser. |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US8021658B2 (en) | 2001-05-25 | 2011-09-20 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| US20050175625A1 (en) * | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| US20090110702A1 (en) * | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
| US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
| US7084246B2 (en) * | 2003-04-17 | 2006-08-01 | Molecular Logix, Inc. | Epidermal growth factor agonists |
| AU2012268864B2 (en) * | 2003-06-27 | 2016-01-21 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| AU2011265359B9 (en) * | 2003-06-27 | 2014-04-10 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| AU2015242981B2 (en) * | 2003-06-27 | 2017-10-19 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| MXPA05014155A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| CN1930187B (zh) * | 2003-06-27 | 2015-08-19 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| DK1940461T3 (da) * | 2005-11-02 | 2014-03-31 | Univ Duke | Samtidig kemoterapi og immunterapi |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| US9340601B2 (en) * | 2007-03-01 | 2016-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Splice variants of the EGF receptor |
| JP5618549B2 (ja) | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤 |
| JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途 |
| WO2009102493A2 (en) * | 2008-02-12 | 2009-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Use of egfrviii to identify and target cancer stem cells |
| EP2690175B1 (de) * | 2008-09-02 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6 |
| SG181628A1 (en) | 2009-12-22 | 2012-07-30 | Celldex Therapeutics Inc | Vaccine compositions |
| DK2640842T3 (en) * | 2010-11-17 | 2018-08-13 | Aduro Biotech Inc | Methods and compositions for inducing an immune response to EGFRVIII |
| CN104780938A (zh) | 2012-08-02 | 2015-07-15 | 小利兰·斯坦福大学托管委员会 | 用于肿瘤治疗的基于EGFRvIII序列的肽疫苗 |
| WO2015142713A1 (en) * | 2014-03-17 | 2015-09-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for reducing c/ebp homologous protein activity in myeloid-derived suppressor cells |
| TWI731535B (zh) | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| CA2968510C (en) | 2014-11-25 | 2020-11-03 | Pharmabcine Inc. | Novel egfrviii antibody and composition comprising same |
| CA2982533A1 (en) | 2015-04-13 | 2016-10-20 | Aduro Biotech, Inc. | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
| HK1250662A1 (zh) | 2015-04-13 | 2019-01-11 | Aduro Biotech, Inc. | 用於治疗癌症的免疫原性融合蛋白 |
| SG11201806597XA (en) * | 2016-02-15 | 2018-09-27 | Samsung Life Public Welfare Foundation | ANTIBODY AGAINST EGFRvIII AND USE THEREOF |
| WO2017142294A1 (ko) * | 2016-02-15 | 2017-08-24 | 사회복지법인 삼성생명공익재단 | EGFRvIII에 대한 항체 및 이의 용도 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69025946T2 (de) * | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| JP2690814B2 (ja) * | 1991-09-03 | 1997-12-17 | 山之内製薬株式会社 | ピラゾロトリアゾール誘導体 |
| CA2261433A1 (en) | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| ATE262586T1 (de) * | 1994-11-28 | 2004-04-15 | Univ Jefferson | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin |
-
1995
- 1995-11-28 AT AT95943342T patent/ATE262586T1/de not_active IP Right Cessation
- 1995-11-28 EP EP95943342A patent/EP0796277B1/de not_active Expired - Lifetime
- 1995-11-28 WO PCT/US1995/015401 patent/WO1996016988A1/en not_active Ceased
- 1995-11-28 JP JP51898296A patent/JP4620808B2/ja not_active Expired - Lifetime
- 1995-11-28 DE DE69532767T patent/DE69532767T2/de not_active Expired - Lifetime
- 1995-11-28 CA CA002206343A patent/CA2206343C/en not_active Expired - Lifetime
-
1997
- 1997-05-21 US US08/861,423 patent/US6224868B1/en not_active Expired - Lifetime
-
2007
- 2007-06-26 JP JP2007167580A patent/JP2007297398A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007297398A (ja) | 2007-11-15 |
| JP4620808B2 (ja) | 2011-01-26 |
| CA2206343C (en) | 2009-04-07 |
| EP0796277A1 (de) | 1997-09-24 |
| JPH10509878A (ja) | 1998-09-29 |
| DE69532767T2 (de) | 2004-08-12 |
| WO1996016988A1 (en) | 1996-06-06 |
| CA2206343A1 (en) | 1996-06-06 |
| DE69532767D1 (en) | 2004-04-29 |
| US6224868B1 (en) | 2001-05-01 |
| EP0796277A4 (de) | 2001-01-24 |
| EP0796277B1 (de) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69532767D1 (en) | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin | |
| NZ514228A (en) | Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation | |
| WO2001098335A3 (en) | Transgenic algae for delivering antigens to an animal | |
| MA24638A1 (fr) | Vaccin | |
| NO20091761L (no) | Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav | |
| WO2005066204A3 (en) | Neutralizing epitope-based growth enhancing vaccine | |
| NZ331176A (en) | Receptor protein designated 2F1, DNA encoding 2F1, preparation and use thereof | |
| MY125202A (en) | Vaccine | |
| IL138075A0 (en) | Vaccines, immunotherapeutics and methods for using the same | |
| EP0815125A4 (de) | gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER | |
| EP1245676A4 (de) | Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung | |
| ATE328068T1 (de) | Papillomavirus vakzine | |
| ATE194291T1 (de) | Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus | |
| WO2008057235A3 (en) | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | |
| BR9809656A (pt) | Composição imunopotencializante | |
| BR9912176A (pt) | Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos | |
| EE200100549A (et) | Meetod fibroosi ravimiseks integriini alfa-4 subühiku antagonistide abil | |
| AU7237391A (en) | Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine | |
| HUP9701586A2 (hu) | Javított inaktivált vakcinák | |
| BG101038A (bg) | Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък | |
| SG146662A1 (en) | Method | |
| ATE248601T1 (de) | Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4 | |
| NO984052L (no) | Rekombinante, adenovirale vektorer for human tumorgenterapi | |
| ES2143996T3 (es) | Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv. | |
| DE60313437D1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |